From hospital-acquired infections to healthcare-associated infections: scientific development of the problem


DOI: https://dx.doi.org/10.18565/epidem.2019.9.1.14-22

Tutelyan A.V., Akimkin V.G., Marin G.G.

Central Research Institute of Epidemiology, Russian Federal Service for Surveillance on Consumer Rights Protection and Human Well-Being, Moscow, Russia
Healthcare-associated infections (HAIs) represent a multidisciplinary problem due to the widespread occerence, negative consequences for the patients’ health, staff health and the state economy, and relevance of this problem has not diminished for decades. As early as in the late 70s of the last century, academician V.I. Pokrovsky noted the need for a systematic scientific approach to the evaluation of this problem, the development of the scientific foundations of the epidemiological surveillance of the HAIs, and the creation of a regulatory and methodological framework. The article is devoted to the issues of diagnostics, treatment and prophylaxis of HAIs in the Russian Federation, various areas of scientific work on the improvement of measures for the controlling and preventing HAIs, including analysis of the epidemiological risks associated with the spread of HAI pathogens; introduction of new methods and means for their laboratory diagnostics; professional advancement of specialists in the framework of educational activities; active international cooperation, as well as the improvement of the regulatory and methodological framework. The contribution of Central Research Institute of Epidemiology of the Russian Federal Service for Surveillance on Consumer Rights Protection and Human Well-Being to the solution of the problem of HAIs is noted.

Literature


  1. Pokrovsky V.I., Akimkin V.G., Briko N.I., Brusina E.B., Blagonravova A.S., Zueva L.P., Kovalishena O.V., Stasenko V.L., Tutelyan A.V., Feldblyum I.V., Shkarin V.V. [Terminologic aspects of infections associated with administration of medical aid]. Zhurnal mikrobiologii. epidemiologii i immunobiologii 2011; (5): 122–5. . (In Russ.).
  2. Akimkin V.G., Tutelyan A.V. [Current directions of scientific researches in the field of infections, associated with the medical care, at the present stage]. Zdorovye naseleniya i sreda obitaniya 2018; (4): 46–50. (In Russ.).
  3. Akimkin V.G., Tutelyan A.V., Brusina E.B. [Topical areas of researches in the nonspecific prevention of health care-associated infections]. Èpidemiologiâ i infekcionnye bolezni. Аktual’nye voprosy 2014; (2): 40–4. (In Russ.).
  4. Pittet D., Allegranzi B., Boyce J. The World Health Organization guidelines on hand hygiene in health care and their consensus recommendations. Infect Control Hosp. Epidemiol. 2009; 30(7): 611–22. https://doi.org/10.1086/ 600379.
  5. Naygovzina N.B., Popova A.Yu., Biryukova E.E., Ezhlova E.B., Igonina E.P., Pokrovsky V.I., Akimkin V.G., Tutelyan A.V., Shestopalov N.V., Krayevoy S.A., Kostenko N.A., Briko N.I., Brusina E.B., Zuyeva L.P., Feldblum I.V., Shkarin V.V., Kozlov R.S., Stasenko V.L., Golubkova A.A., Sukhikh G.T., Priputnevich T.V., Shmakov R.G., Zubkov V.V., Shkoda A.S., Shumilov V.I., Mitrokhin S.D., Ershova O.N., Selkova Е.P., Grenkova T.A., Ivanov I.V., Shvabsky O.R. [Optimization of the system of measures for control and prevention of healthcare-associated infections in the Russian Federation]. Èpidemiologiâ i infekcionnye bolezni. Аktual’nye voprosy 2018; (1): 6–14. (In Russ.).
  6. Brouqui P., Boudjema S., Aladro A.S., Chabrière E., Florea O., Nguyen H., Dufour J.C. New approaches to prevent healthcare-associated infection. Clin. Infect. Dis. 2017; 65(1): S50–4. https://doi.org/10.1093/cid/cix433
  7. Edelstein M.V., Sukhorukova M.V., Skleenova E.Yu., Ivanchik N.V., Mikotina A.V., Sheck E.A., Dekhnich A.V., Azizov I.S., Kozlov R.S. issledovatelskaya gruppa «MARAFON». [Antimicrobial resistance of nosocomial Pseudomonas aeruginosa isolates in Russia: results of multicenter epidemiological study «MARATHON» 2013–2014]. Klinicheskaya mikrobiologiya i antimikrobnaya khimioterapiya 2017; 19(1): 37–41. (In Russ.).
  8. [A list of bacteria that urgently require the creation of new antibiotics]. News who. 27 February 2017. https://www.who.int/news-room/detail/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed. (In Russ.).
  9. Lewis K. Persister cells, dormancy and infectious disease. Nat. Rev. Microbiol. 2007; 5: 48–56.
  10. Lewis K. Persister cells. Annu Rev. Microbiol. 2010; 64: 357–72. DOI:10.1146/annurev.micro.112408.134306.
  11. El-Registan G.I., Nikolaev Yu.A., Mulyukin A.L., Loiko N.G., Demkina E.V., Pisarev V.M., Gaponov A.M., Tutelyan A.V. [Persistence appearance – forms and mechanisms of population survival]. Meditsinskiy alfavit 2014; 2(10): 49–54. (In Russ.).
  12. Gefen O., Balaban N. The importance of being persistent: heterogeneity of bacterial populations under antibiotic stress. FEMS Microbiol. Rev. 2009; 33: 704–17.
  13. Balaban N.Q., Gerdes K., Lewis K., McKinney J.D. A problem of persistence: still more questions than answers? Nat. Rev.Microbiol. 2013; 11: 587–91.
  14. Tutelyan A.V., Gaponov A.M., Pisarev V.M., Elregistan G.I. [Microbial dormancy and prevention of healthcare-associated infections]. Terapevticheskiy arkhiv 2015; 87(11): 103–8. . (In Russ.).
  15. Maisonneuve E., Gerdes K. Molecular mechanisms underlying bacterial persisters. Cell. 2014; 157: 539–48. DOI: 10.1016/j.cell.2014.02.050
  16. Kolodkin-Gal I., Sat B., Keshet A., Engelberg-Kulka H. The communication factor EDF and the toxin-antitoxin module mazEF determine the mode of action of antibiotics. PLoS Biol 2008; 6: e319. https://doi.org/10.1371/ journal.pbio.0060319
  17. Some «Hospital-Acquired» Infections Traced to Patient’s Own Microbiome/ Posted on October 23rd, 2018 by Dr. Francis Collins.
  18. Lin D.M., Koskella B., Lin H.C. Phage therapy: An alternative to antibiotics in the age of multi-drug resistance. World J. Gastrointest. Pharmacol. Ther. 2017; 8(3): 162–73. DOI: 10.4292/wjgpt.v8.i3.162.
  19. Manrique P., Dills M., Young M.J. The human gut phage community and its implications for health and disease. Viruses 2017; 9(6): 1–19.
  20. O’Neill J., ed. Tackling drug-resistant infections globally: final report and recommen-dations. London: The Review on Antimicrobial Resistance, 2016. http://amrreview.org/sites/default/files/160518_Final paper with cover.pdf
  21. Gill J., Young, R.F. Therapeutic applications of phage biology: history, practice and recommendations. In: Miller A.A., Miller.F. eds.). Emerging trends in antibacterialdiscovery: answering the call to arms. Norfolk: Caister Academic Press, 2011; 367–407.
  22. Kutter E.M., Kuhl, S.J., Abedon S.T. Re-establishing a place for phage therapy in western medicine. Future Microbiol. 2015; 10: 685–8. DOI: 10.2217/fmb.15.28
  23. Pirnay J.P., Merabishvili M., van Raemdonck H., De Vos D., Verbeken G. Bacteriophage Production in Compliance with Regulatory Requirements. Methods Mol. Biol. 2018; 1693: 233–52.
  24. Sillankorva S. Isolation of Bacteriophages for Clinically Relevant Bacteria. Methods Mol. Biol. 2018; 1693: 23-30. DOI: 10.1007/978-1-4939-7395-8_3.
  25. Akimkin V.G., Darbeeva O.S., Kolkov V.F. [Historical and modern aspects of bacteriophages application: experience and prospects]. Klinicheskaya praktika 2010; (4): 48–54. (In Russ.).
  26. Maltsev S.V., Mansurova G.Sh. [What is biofilm]. Prirodnaya meditsina: klinicheskiye issledovaniya 2013; 1(13): 86–9. (In Russ.).
  27. Seifert H., Jansen B., Widmer A.F., Farr B.M. Central-venous catheters. In: Seifert H., Jansen B., Farr B.M. (eds.). Catheter-related infections. 2nd ed. New York: Marcel Dekker, 2004; 293–315.
  28. Berezhansky B.V., Zhevnerev A.A. [Catheter-associated infections of the blood flow]. Klinicheskaya mikrobiologiya i antimikrobnaya khimioterapiya 2006; (2): 130–45. (In Russ.).
  29. Deshpande K., Hatem C., Ulrich H.L., Currie B.P., Aldrich T.K., Bryan-Brown C.W. et al. The incidence of infectious complications of central venous catheters at the subclavian, internal jugular, and femoral sites in an intensive care unit population. Crit. Care Med. 2005; 33: 13–20.
  30. Lyamin A.V., Botkin E.A., Zhestkov A.V. [Methods of detection of biofilms in medicine: opportunities and prospects]. Klinicheskaya mikrobiologiya i antimikrobnaya khimioterapiya 2012; 14(1): 17–22. (In Russ.).
  31. Coenye T., Nelis H.J. In vitro and in vivo model systems to study microbial biofilm formation. Microbiol Meth. 2010; 83(2): 89–105.
  32. Kirker K.R., Secor P.R., James G.A., Fleckman P., Olerud J.E., Stewart P.S. Loss of viability and induction of apoptosis in human keratinocytes exposed to Staphylococcus aureus biofilms in vitro. Wound Regen 2009; 17(5): 690–9.
  33. Esteban J., Molina-Manso D., Spiliopoulou I., Cordero-Ampuero J., Fernandez-Roblas R., Foka A., Gomez-Barrena E. Biofilm development by clinical isolates of Staphylococcus spp. from retrieved orthopedic prostheses. Acta Orthopaedica 2010; 81(6): 674–9.


About the Autors


Prof. Aleksey V. Tutelyan, MD, Corresponding Member of the Russian Academy of Sciences; Head, Laboratory of Healthcare-Associated Infections, Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being, Moscow, Russia; е-mail: bio-tav@yandex.ru; ORCID: http://orcid.org/ 0000-0002-2706-6689, eLibrary SPIN: 8150-2230
Prof. Vasiliy G. Akimkin, MD, Аcademician of the Russian Academy of Sciences, Director, Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being, Moscow, Russia; e-mail: vgakimkin@yandex.ru; ОRCID: http://orcid.org/0000-0003-4228-9044
German G. Marin, MD, Leading Researcher, Laboratory of Healthcare-Associated Infections, Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being, Moscow, Russia; е-mail: ger-marin@ yandex.ru; ORCID: http://orcid.org/0000-0003-2179-8421


Similar Articles


Бионика Медиа